The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).
Jens Ricke
Consultant or Advisory Role - Sirtex Medical
Honoraria - Bayer; Sirtex Medical
Research Funding - Bayer; Sirtex Medical
Kerstin Schuette
Honoraria - Bayer
Other Remuneration - Bayer
Olivier Rosmorduc
Honoraria - Bayer; Roche
Markus Peck-Radosavljevic
No relevant relationships to disclose
Chris Verslype
Research Funding - Bayer; Sirtex Medical
Bruno Sangro
Consultant or Advisory Role - Bayer Schering Pharma; Sirtex Medical
Honoraria - Bayer Schering Pharma; Sirtex Medical
Jerzy Walecki
No relevant relationships to disclose
Heinz-Josef Klumpen
Research Funding - Bayer Schering Pharma
Bora Peynircioglu
No relevant relationships to disclose
Suayib Yalcin
No relevant relationships to disclose
Carlo Bartolozzi
No relevant relationships to disclose
Holger Amthauer
Research Funding - Sirtex Medical
Peter Malfertheiner
Consultant or Advisory Role - Bayer; Sirtex Medical
Honoraria - Bayer; Sirtex Medical
Research Funding - Bayer; Sirtex Medical
Other Remuneration - Bayer; Sirtex Medical